This review distinguishes itself by integrating recent findings across multiple axes of cancer immunotherapy, highlighting novel cellular contributors within the TME, such as antigen-presenting CAFs and CD8+CD103+ tissue-resident memory T cells [14], and exploring state-of-the-art technological platforms for spatial and molecular characterization. This evidence concerns the gene CD8A and cancer.